Default image

Collection description

This collection contains guidelines, forms and documents related to accessing alglucosidase alfa (Myozyme®) under the Life Saving Drugs Program for patients with:

  • adult late-onset Pompe disease
  • infantile-onset Pompe disease
  • juvenile late-onset Pompe disease.

Click to view the Myozyme® product information on the Therapeutic Goods Administration website.


We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Last updated: 
3 February 2021
Publication type: 
Health sector